ciliary neurotrophic factor (CNTF)

Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Neuroprotective treatment promising for macular telangiectasiaThe class of molecules called “neurotrophic factors” has been demonstrated to reduce the rate of photoreceptor cell loss during retinal regeneration.
Novel modalities expand glaucoma therapeutic arsenalActive research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.
Therapeutic advances in glaucoma focus on retinal ganglion cell pathologyFindings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.